Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Health Canada is inviting stakeholder feedback on a draft guideline that explains how hospitals can comply with recent changes in the regulation that make it mandatory for them to report medical device incidents (MDIs) and serious adverse drug reactions (ADRs) to the government within 30 calendar days.
Currently, only device and drug companies are required to report MDIs and/or serious ADRs, whereas reporting by health-care institutions and consumers is voluntary. In June, the Canadian government changed the Medical Device and Food and Drugs regulations, making it mandatory for hospitals to report these incidents because, it said, a potentially significant number of MDIs and serious ADRs go unreported.
The government believes the collection and assessment of this real-world information will help Health Canada better monitor the safety of therapeutic products once they are on the market.
The new draft guideline clarifies that if an MDI or serious ADR incident is documented within the hospital, then the hospital is required to report it to Health Canada regardless of whether the incident originated outside of a hospital setting or whether the patient was admitted to hospital or not.
Specifically, reporting is mandatory in relation to MDIs and serious ADRs that are "in a hospital’s control." This means that hospitals would be required to submit incidents documented by health-care professionals within their facilities, but would not be required to further investigate the event with the institution where the MDI/serious ADR originated. They are, however, encouraged to follow up the matter with the concerned other health-care institution, e.g., a nursing home, to obtain the required information to submit a more complete report.
Health Canada initially proposed that the mandatory reporting requirement should only apply to hospitals that provided acute-care services. (Also see "Canada Proposes 30-Day Limit For Hospitals To Report Safety Incidents With Devices" - Medtech Insight, 30 Jun, 2017.) It has since broadened the scope of the regulations to capture incidents from potentially important facilities, such as chronic-care and extended-care hospitals and mental-health facilities, where treatment of such reactions/incidents may occur.
Comments on the draft guideline will be accepted through Aug. 29.
From the editors of Scrip Regulatory Affairs
In Vivo: strategic insights for life sciences decision-maker...
<p><span>Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.</span></p>
Biomedtracker: follow the drug development process
03 Apr 2017
Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.
Scrip: industry news and insights
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018. <br />
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Looking for more products Product Finder
